FR25C1010I2 - Compose de cycle spiro contenant de l'azote et son utilisation medicale - Google Patents

Compose de cycle spiro contenant de l'azote et son utilisation medicale

Info

Publication number
FR25C1010I2
FR25C1010I2 FR25C1010C FR25C1010C FR25C1010I2 FR 25C1010 I2 FR25C1010 I2 FR 25C1010I2 FR 25C1010 C FR25C1010 C FR 25C1010C FR 25C1010 C FR25C1010 C FR 25C1010C FR 25C1010 I2 FR25C1010 I2 FR 25C1010I2
Authority
FR
France
Prior art keywords
spirocycle
compound containing
containing nitrogen
medical use
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR25C1010C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR25C1010(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of FR25C1010I1 publication Critical patent/FR25C1010I1/fr
Application granted granted Critical
Publication of FR25C1010I2 publication Critical patent/FR25C1010I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR25C1010C 2009-07-31 2025-02-28 Compose de cycle spiro contenant de l'azote et son utilisation medicale Active FR25C1010I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31
US27413709P 2009-08-13 2009-08-13
PCT/JP2010/062873 WO2011013785A1 (fr) 2009-07-31 2010-07-30 Composé de cycle spiro contenant de l'azote et son utilisation médicale

Publications (2)

Publication Number Publication Date
FR25C1010I1 FR25C1010I1 (fr) 2025-04-25
FR25C1010I2 true FR25C1010I2 (fr) 2026-02-06

Family

ID=43529436

Family Applications (1)

Application Number Title Priority Date Filing Date
FR25C1010C Active FR25C1010I2 (fr) 2009-07-31 2025-02-28 Compose de cycle spiro contenant de l'azote et son utilisation medicale

Country Status (36)

Country Link
US (4) US8609647B2 (fr)
EP (3) EP3181570A1 (fr)
JP (9) JP5520158B2 (fr)
KR (1) KR101773208B1 (fr)
CN (1) CN102510865B (fr)
AR (1) AR077497A1 (fr)
AU (1) AU2010278066B2 (fr)
BR (1) BR112012002157B1 (fr)
CA (1) CA2767899C (fr)
CO (1) CO6491052A2 (fr)
CY (2) CY1118747T1 (fr)
DK (1) DK2460806T3 (fr)
ES (1) ES2616705T3 (fr)
FI (1) FIC20250012I1 (fr)
FR (1) FR25C1010I2 (fr)
HR (1) HRP20170447T1 (fr)
HU (2) HUE033070T2 (fr)
IL (1) IL217048A (fr)
LT (2) LT2460806T (fr)
ME (1) ME02667B (fr)
MX (1) MX2012001313A (fr)
MY (1) MY163495A (fr)
NL (1) NL301321I2 (fr)
NO (1) NO2025014I1 (fr)
NZ (1) NZ597994A (fr)
PE (1) PE20121276A1 (fr)
PL (1) PL2460806T3 (fr)
PT (1) PT2460806T (fr)
RS (1) RS55913B1 (fr)
RU (1) RU2630694C2 (fr)
SG (1) SG176918A1 (fr)
SI (1) SI2460806T1 (fr)
SM (1) SMT201700166T1 (fr)
TW (1) TWI466885B (fr)
WO (1) WO2011013785A1 (fr)
ZA (1) ZA201200689B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (fr) * 2009-09-04 2013-02-06 Biogen Idec Inc Inhibiteurs hétéroaryles de btk
KR101541086B1 (ko) * 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
PT2796460T (pt) 2011-12-21 2018-11-05 Shanghai hengrui pharmaceutical co ltd Derivado pirrole de anel heteroarilo de seis membros, método de preparação do mesmo e suas utilizações médicas
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
JP6427497B2 (ja) * 2013-10-21 2018-11-21 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
MX2016015613A (es) * 2014-05-28 2017-04-13 Astrazeneca Ab Procesos para la preparacion de azd5363 e intermedios novedosos utilizados en el mismo.
CA2991020A1 (fr) * 2015-07-07 2017-01-12 Japan Tobacco Inc. Procede de production de derive de 7h-pyrollo[2,3-d]pyrimidine et intermediaire correspondant
WO2017013270A1 (fr) 2015-07-23 2017-01-26 Universite De Strasbourg Utilisation d'un inhibiteur de la signalisation de la leptine pour la protection des reins de patients atteints de ciliopathie
MY196541A (en) * 2015-09-24 2023-04-19 Leo Pharma As Treatment of Alopecia Areata
JP6767491B2 (ja) * 2015-09-25 2020-10-14 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法
DK3405197T3 (da) 2016-01-21 2023-11-27 Leo Pharma As Topisk behandling af håndeksem
WO2018026798A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs de nmda spiro-lactame et leurs procédés d'utilisation
KR20190084299A (ko) * 2016-11-23 2019-07-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤로 6-원 헤테로방향족 고리 유도체의 제조 방법 및 그의 중간체
BR112019012688A2 (pt) * 2016-12-21 2019-11-19 Japan Tobacco Inc método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo
EP3559003B1 (fr) * 2016-12-21 2022-08-24 Japan Tobacco Inc. Formes cristallines d'un inhibiteur de janus kinase
TWI790218B (zh) * 2016-12-21 2023-01-21 日商日本煙草產業股份有限公司 7Ｈ－吡咯并[2,3－ｄ]嘧啶衍生物的製造方法及其共結晶
WO2018134352A1 (fr) 2017-01-20 2018-07-26 Leo Pharma A/S Amines bicycliques utilisés en tant que nouveaux inhibiteurs de kinase jak
RU2761626C2 (ru) * 2017-02-03 2021-12-13 Лео Фарма А/С ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ
US11149039B2 (en) * 2017-10-10 2021-10-19 Biogen Inc. Process for preparing spiro derivatives
PE20211455A1 (es) * 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CN112384514A (zh) * 2018-07-06 2021-02-19 利奥制药有限公司 作为janus激酶抑制剂的新的氨基-咪唑并嘧啶衍生物及其药物用途
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
KR20220008893A (ko) 2019-05-15 2022-01-21 레오 파마 에이/에스 피부 홍반성 루푸스의 치료
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
WO2022117075A1 (fr) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 Composé azacyclique, son procédé de préparation et son utilisation
WO2022143629A1 (fr) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 Réactif et procédé pour le traitement de maladies ou d'affections cutanées associées à un agent antitumoral
WO2023202989A1 (fr) 2022-04-20 2023-10-26 Leo Pharma A/S Traitement de l'alopécie fibrosante frontale
AU2024229918A1 (en) 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024194105A1 (fr) 2023-03-17 2024-09-26 Leo Pharma A/S Méthode de traitement de l'eczéma de la main chronique chez des patients ayant un eczéma de main chronique modéré à sévère
WO2024225445A1 (fr) 2023-04-27 2024-10-31 Japan Tobacco Inc. Forme cristalline de delgocitinib
WO2025085050A1 (fr) * 2023-10-16 2025-04-24 Leo Pharma A/S Traitement de l'alopécie fibrosante frontale

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4611524B2 (ja) 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
DK1519939T5 (da) * 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
JPWO2005047286A1 (ja) * 2003-11-13 2007-05-31 小野薬品工業株式会社 スピロ複素環化合物
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
EP2354140A1 (fr) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines en tant qu'inhibiteurs de kinase
WO2007007919A2 (fr) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Nouveaux composes
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007084667A2 (fr) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Inhibiteurs de kinase heterobicycliques fusionnes
WO2007103719A2 (fr) 2006-03-03 2007-09-13 Incyte Corporation MODULATEURS DE LA 11-β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
WO2008029237A2 (fr) 2006-09-05 2008-03-13 Pfizer Products Inc. Polythérapies destinées au traitement de l'arthrite rhumatoïde
CN101563323B (zh) 2006-12-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US20110201599A1 (en) 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (fr) 2009-09-04 2013-02-06 Biogen Idec Inc Inhibiteurs hétéroaryles de btk
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野　信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Also Published As

Publication number Publication date
CA2767899A1 (fr) 2011-02-03
RU2630694C2 (ru) 2017-09-12
SG176918A1 (en) 2012-01-30
SI2460806T1 (sl) 2017-04-26
CA2767899C (fr) 2018-08-28
JP2011046700A (ja) 2011-03-10
AU2010278066A1 (en) 2012-03-01
EP3181570A1 (fr) 2017-06-21
KR101773208B1 (ko) 2017-08-31
AU2010278066B2 (en) 2016-04-14
JP2023138641A (ja) 2023-10-02
SMT201700166T1 (it) 2017-05-08
AR077497A1 (es) 2011-08-31
PT2460806T (pt) 2017-02-27
RS55913B1 (sr) 2017-09-29
JP2021183653A (ja) 2021-12-02
US20240150367A1 (en) 2024-05-09
HUE033070T2 (hu) 2017-11-28
CY1118747T1 (el) 2017-07-12
PL2460806T3 (pl) 2017-06-30
ME02667B (fr) 2017-06-20
LTPA2025511I1 (fr) 2025-03-25
EP3858349A1 (fr) 2021-08-04
JP2016029104A (ja) 2016-03-03
MX2012001313A (es) 2012-02-29
CN102510865A (zh) 2012-06-20
US20110136778A1 (en) 2011-06-09
BR112012002157B1 (pt) 2022-02-08
CY2025008I2 (el) 2026-02-25
NZ597994A (en) 2013-08-30
RU2012106344A (ru) 2013-08-27
TWI466885B (zh) 2015-01-01
EP2460806A1 (fr) 2012-06-06
HRP20170447T1 (hr) 2017-05-19
HUS2500013I1 (hu) 2025-03-28
US20230023377A1 (en) 2023-01-26
FIC20250012I1 (fi) 2025-02-28
ES2616705T3 (es) 2017-06-14
BR112012002157A2 (pt) 2020-08-18
IL217048A0 (en) 2012-02-29
JP2014141516A (ja) 2014-08-07
LT2460806T (lt) 2017-02-10
US20140187534A1 (en) 2014-07-03
ZA201200689B (en) 2012-10-31
NO2025014I1 (no) 2025-03-04
JP2018111701A (ja) 2018-07-19
PE20121276A1 (es) 2012-09-27
JP2025109780A (ja) 2025-07-25
CO6491052A2 (es) 2012-07-31
DK2460806T3 (en) 2017-03-20
MY163495A (en) 2017-09-15
US8609647B2 (en) 2013-12-17
KR20120051649A (ko) 2012-05-22
EP2460806B1 (fr) 2017-01-04
EP2460806A4 (fr) 2012-12-26
WO2011013785A1 (fr) 2011-02-03
JP5520158B2 (ja) 2014-06-11
JP2017019877A (ja) 2017-01-26
NL301321I2 (nl) 2025-07-17
CN102510865B (zh) 2015-04-15
CY2025008I1 (el) 2026-02-25
IL217048A (en) 2014-12-31
TW201107325A (en) 2011-03-01
JP2020033384A (ja) 2020-03-05
FR25C1010I1 (fr) 2025-04-25

Similar Documents

Publication Publication Date Title
FR25C1010I2 (fr) Compose de cycle spiro contenant de l'azote et son utilisation medicale
EP2522658A4 (fr) Compose heterocyclique contenant de l'azote et germicide agricole/horticole
EP2336105A4 (fr) Composé hétérocyclique contenant de l'azote et son utilisation
EP2599876A4 (fr) Décomposition biologique d'ocratoxine a en ocratoxine
BR112013001603A2 (pt) ''artigo absorvente descatável''
FR2895676B1 (fr) Composition cosmetique contenant de la glaucine et son utilisation
EP2590573A4 (fr) Rétracteur interne
EP2238083A4 (fr) Élimination biologique d'azote
EP2606069A4 (fr) Anticorps humanisés de la chaîne alpha des anti-récepteurs de l'interleukine-3
EP2640853A4 (fr) Modulation de l'expression de l'alpha synucléine
EP2446807A4 (fr) Dispositif de maintien d'endoscope
EP2531228A4 (fr) Fabrication d'un greffon nerveux biologique de synthèse et son application
EP2555751A4 (fr) Dispositifs médicaux comprenant des médicaments et procédés de fabrication et d'utilisation associés
EP2637574A4 (fr) Sutures autostatiques d'urgence et conditionnement
EP2281816A4 (fr) Nouveau complexe pyrithione/oxyde de zinc cristallin et composite actif physiologique/antibiotique le contenant
EP2494949A4 (fr) Tétine artificielle et récipient d'allaitement l'utilisant
EP2559913A4 (fr) Dispositif d'engrenage planétaire
GB201004200D0 (en) Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
BR112012020349A2 (pt) "artigo do vestúario descartavel"
BRPI0906323A2 (pt) "artigo absorvente descartável do vestuário"
EP2632265A4 (fr) Composition herbicide synergique contenant du penoxsulam et de l'oryzaline
EP2421901A4 (fr) Composition contenant le complexe hc ha et procédés d'utilisation de celle-ci
EP2930211A4 (fr) Composition de résine et récipient médical à médicaments l'utilisant
EP2667853A4 (fr) Liposome et composition d'hygiène corporelle le contenant
BR112012025270A2 (pt) "composição de cuidados pessoais"